EGFR T790M mutation testing within the osimertinib AURA phase I study.
Affiliation
Personalised Healthcare & Biomarkers, AstraZeneca, CambridgeIssue Date
2017-07
Metadata
Show full item recordAbstract
Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. There is no current consensus regarding the best method to detect EGFR T790M mutations. The aim of this study was to describe the concordance between local testing, which used a variety of methods, and central testing, using the cobas(®) EGFR Mutation Test, for EGFR-sensitizing mutations and the T790M resistance mutation.Citation
EGFR T790M mutation testing within the osimertinib AURA phase I study. 2017, 109:9-13 Lung CancerJournal
Lung CancerDOI
10.1016/j.lungcan.2017.04.011PubMed ID
28577957Type
ArticleLanguage
enISSN
1872-8332ae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2017.04.011
Scopus Count
Collections
Related articles
- EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
- Authors: Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, Hammett T, Cantarini M, Barrett JC
- Issue date: 2015 Dec
- EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.
- Authors: Jenkins S, Yang JC, Jänne PA, Thress KS, Yu K, Hodge R, Weston S, Dearden S, Patel S, Cantarini M, Shepherd FA
- Issue date: 2017 Aug
- EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.
- Authors: Li C, Jia R, Liu H, Zhang B, Wang C
- Issue date: 2018 Aug 13
- Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
- Authors: Takahama T, Azuma K, Shimokawa M, Takeda M, Ishii H, Kato T, Saito H, Daga H, Tsuboguchi Y, Okamoto I, Otsubo K, Akamatsu H, Teraoka S, Takahashi T, Ono A, Ohira T, Yokoyama T, Sakai K, Yamamoto N, Nishio K, Nakagawa K
- Issue date: 2020 Jan 1
- Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
- Authors: Minari R, Bordi P, Del Re M, Facchinetti F, Mazzoni F, Barbieri F, Camerini A, Comin CE, Gnetti L, Azzoni C, Nizzoli R, Bortesi B, Rofi E, Petreni P, Campanini N, Rossi G, Danesi R, Tiseo M
- Issue date: 2018 Jan